| Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
|
| Notes: |
Hameatology/Oncology related Prescribing Guidance
Please see our Prescribing Guidelines page for all prescribing guidance relating to this chapter.
Haematology/Oncology related Shared Care Agreements
Please see our Shared Care Agreements page for all shared care agreements (SCAs) relating to this chapter.
|
|
|
| Details... |
| 08.01 |
Cytotoxic drugs |
|
|
| 08.01 |
Drugs for cytotoxic-induced side-effects |
|
|
Calcium Folinate
(Injection)
|
Formulary
 
|
- Folinic acid (as Calcium folinate) 7.5mg per 1ml
- Chemotherapy induced mucositis and myelosuppression
|
|
|
Mesna
(Injection)
|
Formulary
|
- 1m/10ml solution for injection
- Chemotherapy induced neutropenic infection and nephrotoxicity
|
|
|
Mesna
(Tablets)
|
Formulary
|
- 400mg or 600mg tablets
- Chemotherapy induced neutropenic infection and nephrotoxicity
|
|
|
| 08.01.01 |
Alkylating drugs |
|
|
Bendamustine
(Injection)
|
Formulary
|
|
 NICE TA216: Bendamustine for CLL
NICE TA649 Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma
|
Busulfan
(Tablets)
|
Formulary
|
|
|
|
Busulfan
(Injection)
|
Formulary
|
|
|
|
Cyclophosphamide
(Tablets)
|
Formulary
|
|
|
|
Cyclophosphamide
(Injection)
|
Formulary
|
- 500mg,1g and 2g injection
|
|
|
Ifosfamide
(Injection)
|
Formulary
|
|
|
|
Lomustine
(Capsules)
|
Formulary
|
|
|
|
Melphalan
(Tablets)
|
Formulary
|
|
|
|
Melphalan
(Injection)
|
Formulary
|
- 50mg powder and solvent for injection
|
|
|
Chlormethine Hydrochloride (Mustine)
(Injection )
|
 Unlicensed
|
- 10mg powder for reconstitution
|
|
|
| 08.01.02 |
Anthracyclines and other cytotoxic antibiotics |
|
|
Bleomycin
(Injection)
|
Formulary
|
- 15,000 unit powder for injection
|
|
|
Dactinomycin
(Injection)
|
Formulary
|
- 500microgram powder for reconstitution
|
|
|
Daunorubicin
(Injection)
|
Formulary
|
|
|
|
Doxorubicin
(Injection)
|
Formulary
|
- 10mg/5ml, 50mg/25ml, 100mg/50ml and 200mg/100ml injection
|
|
|
Doxorubicin
(Caelyx®)
(Liposomal injection)
|
Formulary
|
|
NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
|
Epirubicin
(Injection)
|
Formulary
|
- 10mg/5ml and 50mg/25ml injection
- 100mg/50ml, 200mg/100ml infusion
|
|
|
Idarubicin
(Injection and capsules)
|
Formulary
|
- 5mg, 10mg and 25mg capsules
- 5mg and 10mg injection
|
|
|
Mitomycin
(Injection)
|
Formulary
|
|
|
|
Mitoxantrone
(Injection)
|
Formulary
|
|
|
|
Pixantrone
(Injection)
|
Formulary
|
|
NICE TA306: Pixantrone monotherapy
|
| 08.01.03 |
Antimetabolites |
|
|
Azacitidine
(Injection)
|
Formulary
|
|
NICE TA218: azacitidine for myelodysplastic syndromes
|
Capecitabine
(Tablets)
|
Formulary
|
|
NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin
NICE TA191: Gastric cancer (advanced) - capecitabine
|
Cladribine
(Injection)
|
Formulary
|
- 10mg tablet
- 10mg/10ml solution for infusion
- 10mg/5ml solution for injection
- For specialist use only in accordance with guidance from cancer network or NICE
|
NICE TA616: Cladribine for treating relapsing–remitting multiple sclerosis
|
Cytarabine
(Injection)
|
Formulary
|
- 100mg/5ml, 500mg/25ml, 1g/10ml, 2g/20ml and 500g/5ml injection
|
|
|
Fludarabine Phosphate
(Injection)
|
Formulary
|
|
NICE TA119: Leukaemia (lymphocytic) - fludarabine
NICE TA29: Leukaemia (lymphocytic) - fludarabine
|
Fludarabine Phosphate
(Tablets)
|
Formulary
|
|
NICE TA29: Leukaemia (lymphocytic) - fludarabine
|
Fluorouracil
(Injection)
|
Formulary
|
- 250mg/10ml, 500ml/20ml, 500mg/10ml and 1g/20ml injection
- 2.5mg/100ml, 2.5mg/50ml and 5mg/100ml infusion
- For topical cream see chapter 13.8.1
|
|
|
Gemcitabine
(Injection)
|
Formulary
|
- Various strengths of infusion
|
NICE TA116: Breast cancer - gemcitabine
NICE TA25: Pancreatic cancer - gemcitabine
NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
|
Mercaptopurine
(Tablets)
|
Formulary
|
- 50mg tablets
- Note: Only the 50mg strength tablets are included on the formulary for gastro indications in adults. 10mg strength tablets are unlicensed specials. Alternate dosing using 50mg/100mg should be considered where daily doses between 50 and 100mgs are required for adults.
- For use in children see paediatric chapter
- For use in Crohn's disease, see chapter 1
|
|
|
Methotrexate
(Tablets)
|
Formulary
|
|
|
|
Pemetrexed
(Injection)
|
Formulary
|
|
NICE TA135: Mesothelioma - pemetrexed disodium
NICE TA181: Lung cancer (non-small cell, first line treatment) - pemetrexed
NICE TA190: Lung cancer (non-small-cell) - pemetrexed (maintenance)
NICE TA402: Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin
|
Clofarabine
(Injection)
|
Unlicensed
|
- 20mg/20ml infusion
- ONLY Approved for use in acute myeloblastic leukaemia in accordance with the criteria set out by the NHS England Cancer Drugs Fund
|
|
|
| 08.01.04 |
Vinca alkaloids and etoposide |
|
|
Etoposide
(Injection)
|
Formulary
|
- 100mg/5ml, 200mg/10ml and 500mg/25ml infusion
|
|
|
Etoposide
(Capsules)
|
Formulary
|
|
|
|
Vinblastine Sulphate
(Injection)
|
Formulary
|
- 1mg/10ml solution for injection
|
|
|
Vincristine Sulphate
(Injection )
|
Formulary
|
- 1mg/1ml, 2mg/2ml and 5mg/5ml injection
|
|
|
Vindesine Sulphate
(Injection)
|
Formulary
|
|
|
|
Vinorelbine
(Capsules)
|
Formulary
|
- 20mg, 30mg and 80mg capsules
|
|
|
Vinorelbine
(Injection)
|
Formulary
|
- 10mg/1ml and 50mg/5ml infusion
|
|
|
| 08.01.05 |
Other antineoplastic drugs |
|
|
Abemaciclib
(Tablets)
|
Formulary
|
- 50mg, 100mg, 150mg film coated tablets
|
NICE TA563: Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
NICE TA579: Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy
|
Atezolizumab
(Injection)
|
Formulary
|
|
NICE TA492: Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
NICE TA520 : Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy
NICE TA525: Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
NICE TA584: Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer
|
Avelumab
(injection)
|
Formulary
|
- 200mg/10ml concentrate for solution for infusion vials
- For use in combination with axitinib in line with NICE TA645 [Not at SFT]
|
NICE TA517: Avelumab for treating metastatic Merkel cell carcinoma
NICE TA645 Avelumab with axitinib for untreated advanced renal cell carcinoma
|
Axitinib
(Tablets)
|
Formulary
|
- 1mg, 3mg, 5mg and 7mg tablets
|
NICE TA333: Axitinib for advanced renal cell carcinoma
NICE TA645 Avelumab with axitinib for untreated advanced renal cell carcinoma
|
Bosutinib
(Tablets)
|
Formulary
|
|
NICE TA401: Bosutinib for previously treated chronic myeloid leukaemia
|
Brigatinib
(Tablets)
|
Formulary
|
|
NICE TA571 :Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib
|
Cabozantinib
(Tablets)
|
Formulary
|
- 20mg, 40mg and 60mg tablets
|
NICE TA542: Cabozantinib for untreated advanced renal cell carcinoma
|
Carfilzomib
(Injection)
|
Formulary
|
- 10mg, 30mg and 60mg infusion
|
NICE TA457 : Carfilzomib for previously treated multiple myeloma
NICE TA657: Carfilzomib for previously treated multiple myeloma
MHRA November 2019 - Carfilzomib (Kyprolis▼): risk of reactivation of hepatitis B virus
MHRA August 2019 - Carfilzomib (Kyprolis▼): reminder of risk of potentially fatal cardiac events
|
Ceritinib
(Capsules)
|
Formulary
|
|
NICE TA395: Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer
NICE TA500: Ceritinib for untreated ALK-positive non-small-cell lung cancer
|
Dabrafenib
(Capsules)
|
Formulary
|
|
NICE TA321:Dabrafenib for BRAF V600 +ve melanoma
NICE TA396:Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
NICE TA544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanom
|
Daratumumab
(Injection)
|
Formulary
|
|
 MHRA Drug Safety Update (Aug 2019): Daratumumab (Darzalex¥): risk of reactivation of hepatitis B virus
|
Defibrotide
(Injection)
|
 Restricted
|
- 200mg (80 mg/mL concentrate for solution for infusion)
- For the treatment of veno-occlusive disease in accordance with treatment of possible hepatic veno-occlusive disease as noted in link below
- Formulary at RUH for this indication
|
Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia
|
Durvalumab
(Injection)
|
Formulary
|
- 50 mg/mL concentrate for solution for infusion
|
NICE TA578: Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation
|
Eribulin
(Injection)
|
Formulary
|
- 0.88mg/2ml solution for injection
|
NICE TA423: Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens
|
Ibrutinib
(Capsules)
|
Formulary
|
|
NICE TA429 : Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation
NICE TA502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma
|
Idelalisib
(Tablets)
|
Formulary
|
|
NICE TA359: Chronic lymphocytic leukaemia - Idelalisib
|
Inotuzumab Ozogamicin
(Injection)
|
Formulary
|
|
NICE TA541: Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia
|
Isatuximab
(injection)
|
Formulary
|
- 20mg/ml concentrate for solution for infusion vials
- For use in combination with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma in line with TA658.
axitinib in line with NICE TA645
|
NICE TA658: Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma
|
Ixazomib
(Capsules)
|
Formulary
|
- 2.3mg, 3mg and 4mg capsules
- To treat relapsed/defractory myeloma in combination with Lenalidomaide and Dexamethasone
- To treat multple myeloma via the Cancer Drugs Fund
|
|
|
Lenvatinib
(Capsules)
|
Formulary
|
- 4mg and 10mg capsules
- Different brand depending upon indication
|
NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
NICE TA551: Lenvatinib for untreated advanced hepatocellular carcinoma
|
Lenvatinib with Everolimus
(Capsules)
|
Formulary
|
- 4mg and 10mg capsules
- Different brand depending upon indication
|
NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
|
Midostaurin
(Capsules)
|
Formulary
|
|
NICE TA523: Midostaurin for untreated acute myeloid leukaemia
|
Nintedanib
(Capsules)
|
Formulary
|
|
NICE TA347 For treating locally advanced, metastatic or locally recurrant non-small-cell lung cancer
|
Palbociclib
(Capsules)
|
Formulary
|
- 75mg, 100mg and 125mg capsules
|
NICE TA495 Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic brest cancer
NICE TA619 Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer
|
Panitumumab
(Injection)
|
Formulary
|
- 100mg/5ml and 400mg/20ml infusion
|
NICE TA439 : Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
|
Pembrolizumab
(Injection)
|
Formulary
|
- 100mg/4ml concentration for solution for infusion
- 50mg powder for concentration for solution for infusion
- Also available from NHS England Cancer Drugs Fund
- NICE does not recommend pembrolizumab with axitinib for untreated advanced renal cell carcinoma (TA650).
|
NICE TA357: Pembrolizumab for melanoma after ipilimumab
NICE TA366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab
NICE TA428: Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy
NICE TA531: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer
NICE TA650: Pembrolizumab with axitinib for untreated advanced renal cell carcinoma (not recommended)
NICE TA661: Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma
|
Polatuzumab vedotin
(Injection)
|
Formulary
|
- 140mg powder for concentrate for solution for infusion vials
- For use in combination with rituximab and bendamustine in line with NICE TA649
|
NICE TA649 Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma
|
Ponatinib
(Tablets)
|
Formulary
|
- 15mg, 30mg and 45mg tablets
|
NICE TA451 : Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia
|
Ruxolitinib
(Tablets)
|
Formulary
|
- 5mg, 10mg, 15mg and 20mg tablets
|
NICE TA386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis
|
Trametinib
(Tablets)
|
Formulary
|
|
MHRA: Trametinib (Mekinist¥): risk of gastrointestinal perforation and colitis
NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
NICE TA544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
|
Trifluridine-tipiracil
(Tablets )
|
Formulary
|
- 15mg/6.14mg and 20mg/8.19mg tablets
|
NICE TA405: Trifluridine–tipiracil for previously treated metastatic colorectal cancer
|
Venetoclax
(Tablets)
|
Formulary
|
|
NICE TA561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia
|
| 08.01.05 |
Amsacrine |
|
|
Amsacrine
(Injection)
|
Formulary
|
- 75mg/1.5ml solution for infusion ampoules and diluent
|
|
|
| 08.01.05 |
Arsenic trioxide |
|
|
Arsenic Trioxide
(Injection)
|
Formulary
|
|
NICE TA526: Arsenic trioxide for treating acute promyelocytic leukaemia
|
| 08.01.05 |
Bortezomib |
|
|
Bortezomib
(Injection)
|
Formulary
|
|
NICE TA129: Multiple myeloma - bortezomib
NICE TA228: 1st line treatment of multiple myeloma
NICE TA311: Bortezomib for induction therapy in multiple myeloma
NICE TA370: Bortezomib for previously untreated mantle cell lymphoma
|
| 08.01.05 |
Brentuximab vedotin |
|
|
Brentuximab
(Injection)
|
Formulary
|
|
NICE TA478 Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma
NICE TA524: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
NICE TA577 Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma
NICE TA641 Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma
|
| 08.01.05 |
Cetuximab |
|
|
Cetuximab
(Injection)
|
Formulary
|
|
NICE TA145: Head and neck cancer - cetuximab
NICE TA439 : Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
NICE TA473: Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck
|
| 08.01.05 |
Dacarbazine and Temozolomide |
|
|
Dacarbazine
(Injection)
|
Formulary
|
- 500mg and 1g infusion
- 100mg and 200mg injection
|
|
|
Temozolomide
(Capsules)
|
Formulary
|
- 5mg, 20mg, 100mg, 140mg, 180mg and 250mg capsules
|
NICE TA121: Glioma (newly diagnosed and high grade)
NICE TA23: Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer)
|
| 08.01.05 |
Erlotinib |
|
|
Erlotinib
(Tablets)
|
Formulary
|
- 25mg, 100mg and 150mg tablets
|
NICE TA227: Lung cancer (non-small-cell) maintenance - erlotinib
NICE TA258: Lung cancer (non-small-cell) 1st line- erlotinib
NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
|
| 08.01.05 |
Hydroxycarbamide |
|
|
Hydroxycarbamide
(Capsules)
|
Formulary
|
- RUH
 SFT and GWR- 500mg capsules
|
3Ts Hydroxycarbamide Shared Care Document
SFT Hydroxycarbamide Shared Care Document
|
| 08.01.05 |
Ipilimumab |
|
|
Ipilimumab
(Injection)
|
Formulary
|
|
NICE TA268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma
NICE TA319: Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma
NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma
MHRA Drug Safety Update (Jan 2019):Ipilimumab (Yervoy): reports of cytomegalovirus (CMV) gastrointestinal infection or reactivation
|
| 08.01.05 |
Pentostatin |
|
|
Pentostatin
(Injection)
|
Formulary
|
|
|
|
| 08.01.05 |
Platinum compounds |
|
|
Carboplatin
(Injection)
|
Formulary
|
- 150mg/15ml, 450mg/45ml, 50mg/5ml and 600mg/60ml infusion
|
|
|
Cisplatin
(Injection)
|
Formulary
|
- 10mg/10ml, 50mg/50ml and 100mg/100ml infusion
|
|
|
Oxaliplatin
(Injection)
|
Formulary
|
- 50mg/10ml, 100mg/20ml and 200mg/40ml infusion
|
NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin
|
| 08.01.05 |
Procarbazine |
|
|
Procarbazine
(Capsules)
|
Formulary
|
|
|
|
| 08.01.05 |
Protein kinase inhibitors |
|
|
Afatinib
(Tablets)
|
Formulary
|
- 20mg, 30mg, 40mg and 50mg tablets
|
NICE TA310: Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer
|
Cabozantinib
(Oral)
|
Formulary
|
|
NICE TA463 : Cabozantinib for previously treated advanced renal cell carcinoma
NICE TA516: Cabozantinib for treating medullary thyroid cancer
NICE TA542: Cabozantinib for untreated advanced renal cell carcinoma
|
Crizotinib
(Tablets)
|
Formulary
|
|
NICE TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cance
|
Dasatinib
(Tablets)
|
Formulary
|
- 20mg, 50mg, 80mg, 100mg and 140mg tablets
|
NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
|
Entrecitinib
(Capsules)
|
Formulary
|
- 100mg, 200mg capsules
- Use in line with NICE TA643 and 644
|
NICE TA 644 Entrectinib for treating NTRK fusion-positive solid tumours
NICE TA643 Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer
|
Everolimus
(Afinitor®)
(Tablets)
|
Formulary
|
- 2.5mg, 5mg and 10mg tablets
- Ensure correct brand is prescribed.
|
NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
NICE TA432: Everolimus for advanced renal cell carcinoma after previous treatment
NICE TA449 : Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
|
Everolimus
(Votubia®)
(Tablets)
|
Formulary
|
- Only at RUH
- 2.5mg, 5mg and 10mg tablets
- Ensure correct brand is supplied
- To be prescribed by specialist centres in accordance with NHSE commissioning policies
|
Clinical Commissioning Policy: Everolimus for refractory focal onset seizures associated with tuberous sclerosis complex (ages 2 years and above)
Clinical Commissioning Policy: Everolimus for refractory focal onset seizures associated with tuberous sclerosis complex (ages 2 years and above)
|
Gefitinib
(Tablets)
|
Formulary
|
|
NICE TA192: Lung cancer (non-small-cell, first line) - gefitinib
NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
|
Gilteritinib
(Tablets)
|
Formulary
|
- 40mg tablets
- Use in line with NICE TA642
|
NICE TA642 Gilteritinib for treating relapsed or refractory acute myeloid leukaemia
|
Imatinib
(Gilvec®)
(Tablets)
|
Formulary
|
- 100mg and 400mg tablets
- Ensure correct brand supplied
|
NICE TA326: Imatinib for the adjuvant treatment of gastrointestinal stromal tumours
|
Imatinib (Generic)
(Tablets)
|
Formulary
|
- 100mg and 400mg tablets
- Also for treatment of Philadelphia Positive Guidelines ALL as per BCSH Guidelines
|
NICE TA425 Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
NICE TA426 Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
|
Nilotinib
(Capsules)
|
Formulary
|
|
NICE TA241: Dasatinib, nilotinib and high dose imatinib for CML
NICE TA251: Dasatinib, nilotinib and imatinib for first line treatment of CML
NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
|
Pazopanib
(Tablets)
|
Formulary
|
|
NICE TA215: Pazopanib in renal cell cancer
|
Regorafenib
(Tablets)
|
Formulary
|
|
NICE TA488: Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours
NICE TA555: Regorafenib for previously treated advanced hepatocellular carcinoma
|
Sorafenib
(Tablets)
|
Formulary
|
|
NICE TA474: Sorafenib for treating advanced hepatocellular carcinoma
NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
|
Sunitinib
(Capsules)
|
Formulary
|
- 12.5mg, 25mg and 50mg capsules
|
NICE TA169: Renal cell carcinoma - sunitinib
NICE TA179: Gastrointestinal stromal tumours - sunitinib
NICE TA449 : Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
|
Tivozanib
(Capsules)
|
Formulary
|
- 890microgram and 1340microgram capsules
|
NICE TA512: Tivozanib for treating advanced renal cell carcinoma
Tivozanib for treating advanced renal cell carcinoma
|
Vemurafenib
(Tablets)
|
Formulary
|
|
NICE TA269: Vemurafenib for treating malignant melanoma
|
| 08.01.05 |
Taxanes |
|
|
Cabazitaxel
(Injection)
|
Formulary
|
|
NICE TA391: Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel
|
Docetaxel
(Injection)
|
Formulary
|
- Various concentrations of infusion
|
NICE TA101: Prostate cancer (hormone-refractory) - docetaxel
NICE TA109: Breast cancer (early) - docetaxel
|
Paclitaxel
(Injection)
|
Formulary
|
- Various strengths of concentration
|
NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
NICE TA476: Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer
|
Paclitaxel
(Abraxane®)
(Injection)
|
Formulary
|
|
NICE TA476: Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer
|
| 08.01.05 |
Topoisomerase I inhibitors |
|
|
Irinotecan hydrochloride
(Injection )
|
Formulary
|
- 500mg/25ml, 300mg/15ml, 100mg/5ml and 40mg/2ml infusion
|
MHRA Drug Safety Update (Mar 2019):Onivyde (irinotecan, liposomal formulations): reports of serious and fatal thromboembolic events
|
Topotecan
(Injection)
|
Formulary
|
|
NICE TA183: Cervical cancer (recurrent) - topotecan
NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
|
Topotecan
(Capsules)
|
Formulary
|
- 250microgram and 1mg capsules
|
NICE TA184: Lung cancer (small-cell) - topotecan
|
| 08.01.05 |
Trabectedin |
|
|
Trabectedin
(Injection)
|
Formulary
|
- 250microgram and 1mg infusion
|
NICE TA185: Soft tissue sarcoma - trabectedin
NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
|
| 08.01.05 |
Trastuzumab |
|
|
Pertuzumab
(Injection)
|
Formulary
|
|
NICE TA424: Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer
NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
NICE TA569: Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer
|
Trastuzumab
(Injection)
|
Formulary
|
- 600mg/5ml injection Herceptin®
- 150mg and 420mg infusion Ontruzant®
- Prescribe by brand. Biosimilar Ontruzant first line option
|
NICE TA208: Gastric cancer (HER2-positive metastatic) - trastuzumab
NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
NICE TA34: Breast cancer - trastuzumab
|
Trastuzumab emtansine
(Kadcyla®)
(Injection)
|
Formulary
|
|
NICE TA458 : Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxan
|
| 08.01.05 |
Tretinoin |
|
|
Tretinoin
(Capsules)
|
Formulary
|
|
|
|
| 08.01.05 |
Vismodegib |
|
|
| 08.02 |
Drugs affecting the immune response |
|
|
Blinatumomab
(Injection)
|
Formulary
|
|
NICE TA450 : Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia
|
| 08.02.01 |
Antiproliferative immunosuppressants |
|
|
Azathioprine
(Tablets)
|
Formulary
|
- 25mg and 50mg tablets
- Chemotherapy/post transplant
|
|
|
Mycophenolate Mofetil
(Oral )
|
Formulary
|
- 250mg capsules
- 500mg tablets
|
Mycophenolate mofetil, mycophenolic acid: new pregnancy-prevention advice for women and men
|
| 08.02.02 |
Corticosteroids and other immunosuppressants |
|
|
Ciclosporin
(Capsules)
|
Formulary
|
- 25mg, 50mg and 100mg capsules
- Indicated for bone marrow stem cell transplant.
- The brand to be dispensed should be specified by the prescriber due to differences in bioavailability.
- Preparations are not interchangeable.
- RUH and SFT - Neoral
|
|
|
Tacrolimus
(Capsules)
|
Formulary
|
- 500microgram, 1mg and 5mg capsules
- Indicated for bone marrow stem cell transplant.
- The brand to be dispensed should be specified by the prescriber due to differences in bioavailability.
- Preparations are not interchangeable.
|
Oral tacrolimus products: reminder to prescribe and dispense by brand name only
|
Ciclosporin
(Capimune ®Deximune®Neoral®)
(Capsules)
|
Formulary
|
- 25mg, 50mg and 100mg capsules
- For SOLID organ transplant patients continue on brand specifed by the specialist.
- Preparations are not interchangeable.
- NHSE commissioner when ciclosporin used for solid organ transplants. Available from Specialist Centres ONLY.
|
|
|
Ciclosporin
(Sandimmun®)
(Injection)
|
Formulary
|
|
|
|
Tacrolimus
(AdoPORT ®Prograf®Advagraf®)
(Capsules)
|
Formulary
|
- AdoPORT 500microgram, 750microgram, 1mg, 2mg and 5mg capsules
- Prograf 500micrograms, 1mg, and 5mg capsules
- Advagraf 500microgram, 1mg, 3mg, 5mg modified release capsules
- For SOLID organ transplant patients continue on brand specifed by the specialist prescriber.
- Preparations are not interchangeable.
- NHSE commissioner when tacrolimus used for solid organ transplants. Available from Specialist Centres ONLY.
|
|
|
|
|
|
|
| 08.02.03 |
Anti-lymphocyte monoclonal antibodies |
|
|
Alemtuzumab
(Injection)
|
Formulary
|
|
Feb 2020 MHRA DSU - Lemtrada▼ (alemtuzumab): updated restrictions and strengthened monitoring requirements following review of serious cardiovascular and immune-mediated reactions
NICE TA312: Alemtuzumab for relapsing‑remitting multiple sclerosis
MHRA Drug Safety Update (May 2019):Lemtrada (alemtuzumab) and serious cardiovascular and immune-mediated adverse reactions
|
Obinutuzumab
(Injection)
|
Formulary
|
|
NICE TA343: Obinutuzumab with chlorambucil for CLL
NICE TA513:Obinutuzumab for untreated advanced follicular lymphoma
|
Ocrelizumab
(injection)
|
Formulary
|
|
NICE TA533: Ocrelizumab for treating relapsing–remitting multiple sclerosis
NICE TA585: Ocrelizumab for treating primary progressive multiple sclerosis
|
Rituximab
(Truxima)
(injection)
|
Formulary
|
- 100mg/10ml and 500mg/50ml infusion
- Prescribe by Brand Biosimilar First Line
|
NICE TA 137 Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma
NICE TA 243 Rituximab for the first-line treatment of stage III-IV follicular lymphoma
NICE TA174 Rituximab for the first-line treatment of chronic lymphocytic leukaemia
NICE TA193 Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia (TA193)
NICE TA226 Rituximab for the first-line maintenance treatment of follicular non-Hodgkin’s lymphoma
NICE TA649 Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma
|
Rituximab
(MabThera®)
(Subcutaneous injection)
|
Formulary
|
- 1400mg/11.7ml injection
- For single agent maintenance for follicular lymphoma according to NHSE Circular SSC 1434 July 2014
- Prescribe by Brand
|
|
|
| 08.02.04 |
Other immunomodulating drugs |
|
|
Dimethyl fumarate
(Oral)
|
Formulary
|
- 120mg and 240mg capsules
- NB Tecfidera brand only licensed for Multiple Sclerosis
- Check full blood counts before prescribing dimethyl fumarate and then every 6 to 12 months. Stop treatment immediately if progressive multifocal leukoencephalopathy is suspected.
|
NICE TA320: Dimethyl fumarate for multiple sclerosis
MHRA DSU Jan 2021 Dimethyl fumarate (Tecfidera): updated advice on the risk of progressive multifocal leukoencephalopathy (PML) associated with mild lymphopenia
MHRA DSU Mar 2015 Dimethyl fumarate (Tecfidera): fatal PML in an MS patient with severe, prolonged lymphopenia
|
Dinutuximab
(Injection)
|
Formulary
|
- 20mg/4.5ml infusion
- Only for use in line with NHSE commissioning (see link below)
|
NICE TA538: Dinutuximab beta for treating neuroblastoma
|
Fingolimod
(Capsules)
|
Formulary
|
|
NICE TA254: Fingolimod for highly active relapsing remitting multiple sclerosis
Clinical Commissioning Policy: Disease Modifying Therapies for Patients with Multiple Sclerosis (MS)
EMC Risk Minimisation materials: Gilenya (fingolimod)
MHRA DSU Jan 2021 Fingolimod (Gilenya): updated advice about the risks of serious liver injury and herpes meningoencephalitis
MHRA DSU Sep 2019 Fingolimod (Gilenya): increased risk of congenital malformations; new contraindication during pregnancy and in women of childbearing potential not using effective contraception
MHRA DSU Dec 2017 Fingolimod (Gilenya): new contraindications in relation to cardiac risk
MHRA DSU Dec 2017 Fingolimod (Gilenya): updated advice about risk of cancers and serious infections
|
Lenalidomide
(Capsules)
|
Formulary
|
|
Immunomodulatory drugs and pregnancy prevention: temporary advice for management during coronavirus (COVID-19)
Lenalidomide (Revlimid): risk of serious hepatic adverse drug reactions – routine monitoring of liver function now recommended
Lenalidomide: risk of thrombosis and thromboembolism
NICE TA 322 Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality
NICE TA 586 Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib
NICE TA171: Lenalidomide for the treatment of multiple myeloma in people who have received at least 2 prior therapies
NICE TA587 Lenalidomide plus dexamethasone for previously untreated multiple myeloma
|
Niraparib
(Capsules)
|
Formulary
|
|
|
|
Nivolumab
(Injection)
|
Formulary
|
|
Oct 2019 - reports of cytomegalovirus (CMV) gastrointestinal infection or reactivation
NICE TA384: Nivolumab for treating advanced (unresectable or metastatic) melanoma
NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma
NICE TA417: Nivolumab for previously treated advanced renal cell carcinoma
NICE TA462 : Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma
NICE TA655: Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy
|
Olaparib
(Oral)
|
Formulary
|
- 50mg capsules
- NB other strengths exist these are not formulary
|
NICE TA381: Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy
NICE TA598: Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy
|
Osimertinib
(Capsules)
|
Formulary
|
|
NICE TA 653: Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer
NICE TA654: Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer
|
Panobinostat
(Capsules)
|
Formulary
|
- 10mg, 15mg and 20mg capsules
|
NICE TA380: Panobinostat for treating multiple myeloma after at least 2 previous treatments
|
Pegaspargase
(Injection)
|
Formulary
|
|
NICE TA408: Pegaspargase for treating acute lymphoblastic leukaemia
|
Pomalidomide
(Capsules)
|
Formulary
|
|
Immunomodulatory drugs and pregnancy prevention: temporary advice for management during coronavirus (COVID-19)
NICE TA388: Pomalidomide for myeloma
NICE TA427: Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib
|
Siponimod
(Tablets)
|
Formulary
|
- 250 microgram and 2mg film coated tablets
|
NICE TA656: Siponimod for treating secondary progressive multiple sclerosis
|
Teriflunomide
(Tablets)
|
Formulary
|
|
Clinical Commissioning Policy: Disease Modifying Therapies for Patients with Multiple Sclerosis (MS)
NICE TA303: Teriflunomide for relapsing remitting MS
|
Thalidomide
(Capsules)
|
Formulary
|
|
Immunomodulatory drugs and pregnancy prevention: temporary advice for management during coronavirus (COVID-19)
NICE TA228: Bortezomib and thalidomide for the first‑line treatment of multiple myeloma
|
| 08.02.04 |
Interferon Alfa |
|
|
Peginterferon Alfa
(Injection)
|
Formulary
|
- 90microgram/0.5ml, 135microgram/0.5ml and 180microgram/0.5ml pre-filled syringes
|
NICE TA106: Hepatitis C - peginterferon alfa & ribavirin
NICE TA200: Hepatitis C - peginterferon alfa & ribavirin
NICE TA300: Hepatitis C - peginterferon alfa
NICE TA75: Hepatitis C - pegylated interferons, ribavirin & alfa interferon
NICE TA96: Hepatitis B - peginterferon alfa
|
Peginterferon Alfa
(Injection )
|
Formulary
|
- 90microgram/0.5ml, 135microgram/0.5ml and 180microgram/0.5ml pre-filled syringes
- For the treament of leukaemia and lymphoma in accordance with cancer network guidelines
- For the treatment of Myeloproliferative Neoplasms e.g Essential Thrombocythaemia, Polycythaemia after hydroxycarbamide or anagralide.
|
|
|
| 08.02.04 |
Interferon beta |
|
|
Interferon Beta
(Injection)
|
Formulary
|
- 30microgram/0.5ml pre-filled (6 million units) syringes
|
Clinical Commissioning Policy: Disease Modifying Therapies for Patients with Multiple Sclerosis (MS)
NICE TA527 Beta interferons and glatiramer acetate for treating multiple sclerosis
|
Interferon Beta
(Extavia®)
(Injection)
|
Formulary
|
- Extavia® 250 microgram/ml powder and solvent for solution for injection
- After reconstitution, each ml contains 250 microgram (8.0 million IU) of recombinant interferon beta-1b
|
Clinical Commissioning Policy: Disease Modifying Therapies for Patients with Multiple Sclerosis (MS)
NICE TA527 Beta interferons and glatiramer acetate for treating multiple sclerosis
|
Interferon Beta
(Rebif®)
(Injection)
|
Formulary
|
- 22micrgoram/0.5ml and 8.8microgram/0.2ml cartridges and pre-filled pens/syringes
- 44microgram/0.5ml cartridges and pre-filled pens/syringes
|
Clinical Commissioning Policy: Disease Modifying Therapies for Patients with Multiple Sclerosis (MS)
NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis
|
Peginterferon Beta-1a
(Injection )
|
Formulary
|
- 63microgram/0.5ml, 94microgram/0.5ml and 125microgram/0.5ml pre-filled pens
|
Clinical Commissioning Policy: Disease Modifying Therapies for Patients with Multiple Sclerosis (MS)
Link NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis
|
| 08.02.04 |
Glatiramer acetate |
|
|
Glatiramer Acetate
(Injection)
|
Formulary
|
- 20mg/1ml and 40mg/1ml injection
|
Clinical Commissioning Policy: Disease Modifying Therapies for Patients with Multiple Sclerosis (MS)
NICE TA527 Beta interferons and glatiramer acetate for treating multiple sclerosis
|
| 08.02.04 |
Lenalidomide, pomalidomide, and thalidomide |
|
|
Clarithromycin
(Tablets)
|
Formulary
|
- RUH only
- Used in combination with lenalidomide and pomalidomide as per DTC899
- 250mg and 500mg tablets
|
|
|
| 08.02.04 |
Mifamurtide |
|
|
Mifamurtide
(Injection)
|
Formulary
|
- 4mg infusion
- When used in line with NICE TA235 (as below) and initiated by specialist centres ONLY
|
NICE TA235: Osteosarcoma - mifamurtide: guidance
|
| 08.02.04 |
Natalizumab |
|
|
Natalizumab
(Injection)
|
Formulary
|
|
Clinical Commissioning Policy: Disease Modifying Therapies for Patients with Multiple Sclerosis (MS)
NICE TA127: Multiple sclerosis - natalizumab
|
| 08.03 |
Sex hormones and hormone antagonists in malignant disease |
|
|
| 08.03.01 |
Oestrogens |
|
|
Diethylstilbestrol
(Tablets)
|
Formulary
|
|
|
|
| 08.03.02 |
Progestogens |
|
|
Medroxyprogesterone Acetate
(Tablets )
|
Formulary
|
- 2.5mg, 5mg, 10mg, 100, 200mg and 400mg tablets
- Specialist initiation only for endometrial cancer
|
|
|
Megestrol Acetate
(Tablets)
|
Formulary
|
- 160mg tablets
- Specialist initiation only for endometrial cancer.
|
|
|
Norethisterone
(Tablets)
|
Formulary
|
- 350microgram and 5mg tablets
- Specialist initiation only for endrometrial cancer.
|
|
|
| 08.03.03 |
Androgens |
|
|
| 08.03.04 |
Hormone antagonists |
|
|
| 08.03.04.01 |
Breast cancer |
|
|
Anastrozole
(Tablets)
|
Formulary
|
|
|
|
Exemestane
(Tablets)
|
Formulary
|
|
|
|
Fulvestrant
(Faslodex®)
|
Formulary
|
- 250mg/5ml pre-filled syringes
- Commissioned by CDF in in combination with abemaciclib , palbciclib or ribociclib for treating hormone receptor-positive, HER2-negative advanced breast cancer (TA579/593/619). NICE does not recommend for treatment of locally advanced or metastatic breast cancer (TA239/503).
|
NICE TA579: Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy
NICE TA593: Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer
NICE TA619: Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer
NICE TA239: Fulvestrant for the treatment of locally advanced or metastatic breast cancer (not recommended)
NICE TA503: Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer (not recommended)
|
Ibandronic Acid
(50mg Tablet)
|
Formulary
|
- Patients from RUH and GWH only -Adjuvant bisphosphonates for breast cancer (see shared care agreement). Under review for SFT.
- For use by oncology only.
- Ibandronic Acid 'off label' indication
- Tablets 50mg daily
|
RUH/GWH Shared care agreement - adjuvant therapy for postmenopausal patients
|
Letrozole
(Tablets)
|
Formulary
|
- 2.5mg tablet
- - For treatment of breast cancer.
- - For the second-line treatment of patients with anovulatory infertility unresponsive to Clomifene at RUH and GWH only. Not included for this indication on the formulary at SFT.
|
|
|
Ribociclib
(Tablets)
|
Formulary
|
|
NICE TA496: Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
NICE TA593 Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer
|
Tamoxifen
(Tablets)
|
Formulary
|
- 10mg, 20mg and 40mg tablets
|
|
|
|
|
|
|
|
|
|
|
| 08.03.04.02 |
Prostate cancer and gonadorelin analogues |
|
|
Radium-223 dichloride
(Injection)
|
Formulary
|
|
NICE TA412: Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases
|
|
|
| 08.03.04.02 |
Gonadorelin analogues |
|
|
Triptorelin
(Injection)
|
First Choice
|
- Triptorelin acetate 3mg SR - 1 monthly injection (Decapeptyl®)
- Triptorelin acetate Depot - 1 monthly injection (Gonapeptyl®)
- Triptorelin pamoate 11.25mg SR - 3 monthly Injection (Decapeptyl®)
- Triptorelin pamoate 22.5mg SR - 6 monthly injection (Decapeptyl®)
- Decapeptyl SR 22.5mg is considered first line LHRH analogue for new patients [1st dose should be a monthly prep to ensure tolerance]. Also consider a switch to 6 monthly preparation for anyone high risk for COVID-19 and currently receiving a 1 month or 3 monthly LHRH in line with guidance below.
- For locally advanced, non-metastatic prostate cancer, as an alternative to surgical castration, or metastatic prostate cancer within the product licence.
|
BSW CCG Managing male patients with prostate cancer on LHRH analogues during COVID-19 pandemic
|
Goserelin Acetate
|
Formulary
|
- 3.6 mg Implant - 1 monthly (Zoladex®)
- 10.8mg Implant - 3 monthly (Zoladex LA ®)
- For locally advanced,non-metastatic prostate cancer, as an alternative to surgical castration, or metastatic prostate cancer within the product licence.
|
|
|
Leuprorelin Acetate
(Injection )
|
Formulary
|
- 3.75mg pre-filled syringes (Prostap® SR DCS) - one month injection
- 11.25mg pre-filled syringes (Prostap® 3 DCS) - 3 month injection
- For locally advanced, non-metastatic prostate cancer, as an alternative to surgical castration, or metastatic prostate cancer as per the licensed indication
- Lutrate® has been discontinued (Jun 19)
|
|
|
Degarelix
(Injection)
|
Formulary
|
|
NICE TA404: Degarelix for treating advanced hormone-dependent prostate cancer
|
| 08.03.04.02 |
Anti-androgens |
|
|
Abiraterone
(Tablets)
|
Formulary
|
|
NICE TA259: Abiraterone for castration resistant prostate cancer
NICE TA387:Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
|
Bicalutamide
(Tablets)
|
Formulary
|
|
|
|
Buserelin
(Nasal spray)
|
Formulary
|
- 100microgram and 150microgram nasal spray
|
|
|
Cyproterone
(Tablets)
|
Formulary
|
|
June 2020 - Cyproterone acetate: new advice to minimise risk of meningioma
|
Darolutamide
(Tablets)
|
Formulary
|
|
NICE TA660: Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer
|
Enzalutamide
(Tablets)
|
Formulary
|
|
NICE TA316: Enzalutamide for prostate cancer
NICE TA377: Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
|
| 08.03.04.03 |
Somatostatin analogues |
|
|
Octreotide
(Short acting Injection)
|
Formulary
|
- 50microgram/1ml, 100microgram/1ml
- Also see palliative care chapter for use in management of high output stomas and fistulas
|
|
|
Octreotide
(Sandostatin Lar®)
(Long Acting Injection)
|
Formulary
|
  Swindon - relief of symptoms associated with acromegaly- 10mg, 20mg and 30mg injection
- Commissioned by NHS England, as per agreed Trust Guidelines. Use product with lowest procurement cost
- Carcinoid Syndrome and Neuroendocrine Tumours
- For the treatment of acromegaly
|
|
|
Lanreotide
(Injection)
|
Formulary
|
- Swindon - relief of symptoms associated with acromegaly
- Commissioned by NHS England, as per agreed Trust Guidelines. Use product with lowest procurement cost.
- 60mg/0.5ml, 90mg/0.5ml and 120mg/0.5ml pre-filled syringe
- Carcinoid Syndrome and Neuroendocrine Tumours
- For the treatment of acromegaly
|
|
|
Lutetium (177Lu) oxodotreotide
(Lutathera)
(Injection)
|
Formulary
|
|
NICE TA539: Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours
|
| .... |
| Non Formulary Items |
Anamorelin
|
Non Formulary
|
|
|
|
Anamorelin
|
Non Formulary
|
|
|
|
Carmustine
(Implant)
|
Non Formulary
|
- 7.7mg implant
- Non Formulary except when used within a specialist centre as per NICE TA
|
NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
|
Chlorambucil
(Leukeran®)
(Tablets)
|
Non Formulary
|
|
|
|
Dexrazoxane
|
Non Formulary
|
For anthracycline extravasation |
|
|
Disodium Levofolinate
(Lvofolinic acid )
|
Non Formulary
|
|
|
|
Ethinylestradol
(Cancer)
|
Non Formulary
|
|
|
|
Fampridine
|
Non Formulary
|
|
|
|
Flutamide
|
Non Formulary
|
|
|
|
Interferon Alfa
(Roferon-A®)
|
Non Formulary
|
- Pre-filled syringes 3 million / 4.5 million / 6 million International Units interferon alfa-2a* per 0.5 millilitres
- For the treament of leukaemia and lymphoma in accordance with cancer network guidelines
- For the treatment of Myeloproliferative Neoplasms e.g Essential Thrombocythaemia, Polycythaemia after hydroxycarbamide or anagralide.
|
|
|
Mycophenolate Sodium
|
Non Formulary
|
|
|
|
Neratinib
|
Non Formulary
|
|
|
|
Olaratumab
(Lartruvo®)
|
Non Formulary
|
Discontinued |
|
|
Oxaliplatin
|
Non Formulary
|
|
|
|
Padeliporfin
|
Non Formulary
|
|
NICE TA546: Padeliporfin for untreated localised prostate cancer
|
Prednisolone
(Post- transplant)
|
Non Formulary
|
|
|
|
Prednisolone
(Immunosuppressant)
|
Non Formulary
|
|
|
|
Raltitrexed
|
Non Formulary
|
|
|
|
Rociletinib
|
Non Formulary
|
|
|
|
Sirolimus
(Rapamune®)
|
Non Formulary
|
- Non Formulary Except when used in accordance with NHSE Commissioning Policy for Solid Organ Transplants within specialist centres (not RUH SFT GWH)
|
|
|
Sonidegib
(Odomzo®)
|
Non Formulary
|
|
|
|
Thiotepa
|
Non Formulary
|
|
|
|
Tioguanine
|
Non Formulary
|
|
|
|
Treosulfan
|
Non Formulary
|
Commissioned as per national guidance in combination with Fludarabine in line with NICE TA640. Condition not treated at GWH/RUH/SFT |
NICE TA 640 Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant
|
Vismodegib
(Capsules)
|
Non Formulary
|
- 150mg capsule
- Not recommended by NICE
|
NICE TA489: Vismodegib for treating basal cell carcinoma
|
Vosaroxin
(Qinprezo)
|
Non Formulary
|
|
|
|
| |
Key |
|
|
|
|
Cytotoxic Drug
|
|
|
Controlled Drug
|
|
High Cost Medicine
|
|
Cancer Drugs Fund
|
|
NHS England |
|
Homecare |
|
CCG |
|
High Cost Drug Approval System |
|
Traffic Light Status Information
|
|
|
